Thus, this creates another opportunity in and of itself. Lastly, Corvus isn't pinning all of its hopes on its selective ITK inhibitor soquelitinib to target AD patients. Matter of fact ...

About 90% of patients with CLL treated with ibrutinib or acalabrutinib develop mutations in BTK C481, while patients receiving the reversible inhibitor pirtobrutinib develop kinase active site ...

(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, to prevent ...

Corvus Pharmaceuticals (CRVS) announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate ...